Abstract
Inhibitors of phosphodiesterase type III (PDE III) enhance cardiac contractile force by elevating the intracellular calcium concentration [Ca2+]i by impairing cAMP degradation thus increasing cAMP levels. The drugs are more effective in healthy than in failing hearts since basal cAMP production is diminished in the latter. However, long term treatment with PDE-III inhibitors does not appear to be beneficial due to increased risk of potentially lethal arrhythmias caused by augmentation of [Ca2+]i. [1). This risk should be absent in Ca2+ sensitizers. Recently, thiadiazinone derivatives have been synthetized in which the potency for Ca2+ sensitization is many-fold larger than the potency for PDE-III inhibition. The Ca2+-sensitizing action resides in the [+]-enantiomers, while the [−]-enantiomers show weak PDE-III inhibition. In the enantiomer pair [+]-EMD 60263 and [−]-EMD 60264, only the former concentration-dependently increased force of contraction in isolated cardiac preparations and myocytes. In the Langendorff-perfused guinea-pig heart, force was reversibly increased, whereas [−]-EMD 60264 even produced a negative inotropic response despite of its PDE inhibitory activity. Heart rate, however, was reduced by both enantiomers. Perfusion pressure remained unaffected. The effects were fully reversible upon wash-out of the enantiomers. [+]-EMD 60263 also enhanced cell shortening of human myocytes from both normal and failing hearts. In contrast to the opposite effects on contractility, both enantiomers prolong the action potential duration by blocking the rapidly activating component of the delayed rectifier K+ current. Thus they also possess class III antiarrhythmic activity. The therapeutic potential of these agents has yet to be assessed in clinical studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, diBianco R, et al. for the PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468–1475, 1991
Feldman MD, Copelas L, Gwathmey JK, Philipps P, Warren SE, Schoen FJ, Grossman W, Morgan JP: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75: 331–339, 1987
Anderson JL, Askins JC, Gilbert EM, Menlove RL, Lutz JR: Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. Am Heart J 111: 466–474, 1986
Schmitz W, von der Leyen H, Meyer W, Neumann J, Scholz H: Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol 14 (Suppl 3): S11–S14, 1989
Schmitz W, Scholz H, Erdmann E: Effects of α- and β-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparations. Trends Pharmacol Sci 8: 447–450, 1987
Fischer TA, Erbel R, Treese N: Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs 44: 928— 945, 1992
Rüegg JC, Morano I: Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol 14 (Suppl 3): S20–S23, 1989
Herzig JW, Feile K, Ruegg JC: Activating effects of AR-L 115 BS on the Ca2+ sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle. Arzneim-Forsch/Drug Res 31 (I): 188–191, 1981
Fujino K, Sperelakis N, Solaro RJ: Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 63: 911–922, 1988
Beier N, Harting J, Jonas R, Klockow M, Lues I, Haeusler G: The novel cardiotonic agent EMD 53 998 is a potent ‘calcium sensitizer’. J Cardiovasc Pharmacol 18: 17–27, 1991
Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, Beier N, Lakatta EG: Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 73: 981–990, 1993
Sanguinetti MC, Jurkiewicz NK: Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96: 195–215, 1990
Tande PM, Bjornstad H, Yang T, Refsum H: Rate-dependent class III antiarrhythmic action, negative chronotropy and positive inotropy of a novel IK blocking drug, UK-68,798: potent in guinea-pig but no effect in rat myocardium. J Cardiovasc Pharmacol 16: 401–410, 1990
Yang T, Tande PM, Refsum H: Negative chronotropic effect of a novel class III antiarrhythmic drug, UK-68,798, devoid of β-blocking action in isolated guinea-pig atria. Br J Pharmacol 103: 1417–1420, 1991
Wallace M, Stupienski RF, Brookes LM, Selnick HG, Claremon DA, Lynch JJ: Cardiac electrophysiological and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anethetized dogs. J Cardiovasc Pharmacol 18: 687–, 1991
Ventura C, Miller R, Wolf H-P, Beier N, Jonas R, Klockow M, Lues I, Hano O, Spurgeon HA, Lakatta EG, Capogrossi MC: Novel diazinone derivatives separate myofilament Ca2+ sensitization and phosphodiesterase III inhibitory effects in guinea pig myocardium. Circ Res 70: 1081–1090, 1992
Lues I, Beier N, Jonas R, Klockow M, Haeusler G: The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol 21: 883–892, 1993
Ohler A, Ravens U: Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther 270: 460–465, 1994
Harding SE, O Gara P, Jones SM, Brown LA, Vescovo G, Poole-Wilson PA: Species dependence of contraction velocity in single isolated cardiac myocytes. Cardioscience 1: 49–53, 1900
Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE: Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 92: 2540–2549, 1995
Wettwer E, Grundke M, Ravens U: Differential effects of the new class lil antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res 26: 1145–1152, 1992
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Ravens, U., Himmel, H.M., Flüss, M., Davia, K., Harding, S.E. (1996). Phosphodiesterase inhibition and Ca2+ sensitization. In: Lamers, J.M.J., Verdouw, P.D. (eds) Biochemistry of Signal Transduction in Myocardium. Developments in Molecular and Cellular Biochemistry, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1275-8_32
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1275-8_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8544-1
Online ISBN: 978-1-4613-1275-8
eBook Packages: Springer Book Archive